Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures the top layer of your skin. Once you know how to inject ...

Weight-loss injections are dominating the market: Where will GLP-1 pills fit in? Glucagon-like peptide-1 (GLP-1) medications have emerged as powerful tools for weight loss. So far, injectable options like Wegovy (semaglutide) and Zepbound (tirzepatide ...

PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic ® (semaglutide) injection 1 mg in adults with type 2 diabetes and early-stage ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures the top layer of your skin. Once you know how to inject ...

Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.

FRESNO, Calif. (KFSN) -- Social media has an abundance of weight loss videos, from the latest diet trends to the most popular fitness programs. But for some like Amber Contino, nutritious foods and exercise aren't enough to reach their weight goal.

A new study led by a researcher at University College London (UCL) suggests that the anti-obesity drug semaglutide may reduce the risk of heart attacks and other serious cardiac events even when people lose little or no weight while taking it.

Americans can now purchase the starter dose of blockbuster weight-loss drug Wegovy as a pill, drug maker Novo Nordisk announced Monday. Other strengths will be available as pills by the end of the week.

Wegovy pill introduction in the U.S. may serve as the turning point that transforms a beleaguered GLP‑1 leader into a viable 2x